SRZN
Surrozen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.76
+0.98%Year over year
Reported trailing growth
- Revenue
- -8.8%
- EBITDA
- —
- EBIT
- -71.1%
- EPS
- —
- Free cash flow
- -86.8%
- Operating cash flow
- -86.3%
Forward estimates
Based on analyst estimates
- Revenue
- -75.6%
- EBITDA
- +74.8%
- EPS
- +91.2%
Three-year CAGR
- Revenue
- -34.7%
- EBITDA
- —
- EBIT
- -64.8%
- Net income
- —
- EPS
- -49.4%
- Free cash flow
- -72.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026